Nationwide trends in glucose-lowering drug use, Denmark, 1999-2014

Clinical Epidemiology

Volumn 8, Issue , 2016, Pages 381-387

  Christensen, Diana Hedevang ^a   Rungby, Jørgen ^b,c   Thomsen, Reimar Wernich ^a  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

^b AARHUS UNIVERSITY   (Denmark)

^c GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

Author keywords

Antidiabetic drugs; Diabetes mellitus; Drug utilization; Registries

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ALPHA GLUCOSIDASE INHIBITOR; ANTIDIABETIC AGENT; DIPEPTIDYL PEPTIDASE IV INHIBITOR; FAST ACTING INSULIN; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; INSULIN; INTERMEDIATE ACTING INSULIN; LONG ACTING INSULIN; MEGLITINIDE; METFORMIN; MIXED FORMULA INSULIN; SODIUM GLUCOSE COTRANSPORTER 2 INHIBITOR; SULFONYLUREA; UNCLASSIFIED DRUG;

ADULT; AGE; AGED; ARTICLE; CONTROLLED STUDY; DENMARK; DRUG USE; DRUG UTILIZATION; HUMAN; PREVALENCE; TREND STUDY;

EID: 84991780905     PISSN: None     EISSN: 11791349     Source Type: Journal    
DOI: 10.2147/CLEP.S113211     Document Type: Article

References (18)

1. McGuire H, Longson D, Adler A, Farmer A, Lewin I; Guideline Development Group. Management of type 2 diabetes in adults: summary of updated NICE guidance. BMJ. 2016;353:i1575.
2. Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyper-glycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2015;38(1):140-149.
3. International Diabetes Federation Guideline Development Group. Global guideline for type 2 diabetes. Diabetes Res Clin Pract. 2014; 104(1):1-52.
4. Diabetesforeningen [webpage on the Internet]. The National Danish Diabetes Registry; 2016. Available from: http://www.diabetes.dk/presse/diabetes-i-tal/det-nationale-diabetesregister.aspx. Accessed March 20, 2016.
5. Schmidt M, Pedersen L, Sorensen HT. The Danish Civil Registration System as a tool in epidemiology. Eur J Epidemiol. 2014;29(8):541-549.
6. Danish Serum Institute [webpage on the Internet]. Statistics on annual sales of medicines in Denmark based on the data from the Register of Medicinal Products Statistics; 2016. Available from: www.medstat.dk/en. Accessed January 19, 2016.
7. Kildemoes HW, Sorensen HT, Hallas J. The Danish National Prescription Registry. Scand J Public Health. 2011;39(7 suppl):38-41.
8. Johannesdottir SA, Horvath-Puho E, Ehrenstein V, Schmidt M, Pedersen L, Sorensen HT. Existing data sources for clinical epidemiology: the Danish national database of reimbursed prescriptions. Clin Epidemiol. 2012;4:303-313.
9. Ehrenstein V, Antonsen S, Pedersen L. Existing data sources for clinical epidemiology: Aarhus University Prescription Database. Clin Epidemiol. 2010;2:273-279.
10. Sharma M, Nazareth I, Petersen I. Trends in incidence, prevalence and prescribing in type 2 diabetes mellitus between 2000 and 2013 in primary care: a retrospective cohort study. BMJ Open. 2016;6(1):e010210.
11. Torre C, Guerreiro J, de Oliveira Martins S, Raposo JF, Martins AP, Leufkens H. Patterns of glucose lowering drugs utilization in Portugal and in the Netherlands. Trends over time. Prim Care Diabetes. 2015; 9(6):482-489.
12. Thomsen RW, Baggesen LM, Svensson E, et al. Early glycaemic control among patients with type 2 diabetes and initial glucose-lowering treatment: a 13-year population-based cohort study. Diabetes Obes Metab. 2015;17(8):771-780.
13. Hampp C, Borders-Hemphill V, Moeny DG, Wysowski DK. Use of antidiabetic drugs in the U.S., 2003-2012. Diabetes Care. 2014;37(5): 1367-1374.
14. Kohro T, Yamazaki T, Sato H, et al. Trends in antidiabetic prescription patterns in Japan from 2005 to 2011. Int Heart J. 2013;54(2):93-97.
15. European Medicine Agency [webpage on the Internet]. European Medicines Agency recommends new contra-indications and warnings for pioglitazone to reduce small increased risk of bladder cancer. Available from: http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2011/07/news_detail_001311.jsp&mid=WC0b01ac058004d5c1. Accessed January 10, 2016.
16. Ehrenstein V, Hernandez RK, Ulrichsen SP, et al. Rosiglitazone use and post-discontinuation glycaemic control in two European countries, 2000-2010. BMJ Open. 2013;3(9):e003424.
17. Thomsen RW, Sorensen HT. Using registries to identify type 2 diabetes patients. Clin Epidemiol. 2014;7:1-3.
18. Thomsen RW, Baggesen LM, Sogaard M, et al. Effectiveness of intensification therapies in Danes with type 2 diabetes who use basal insulin: a population-based study. Diabet Med. Epub 2016 Jun 9.